Refractory T-Cell Non-Hodgkin Lymphoma
Showing 1 - 8 of 8
Adenoid Cystic Skin Carcinoma, Adnexal Carcinoma, Anaplastic Large Cell Lymphoma, ALK-Negative Trial in United States
Recruiting
- Adenoid Cystic Skin Carcinoma
- +38 more
- Biopsy
- +6 more
-
Los Angeles, California
- +35 more
Jan 31, 2023
Recurrent DLBCL, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory DLBCL Trial in Houston (drug, procedure, other, biological)
Recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- +4 more
- Busulfan
- +7 more
-
Houston, TexasM D Anderson Cancer Center
Sep 22, 2022
Hematopoietic Cell Transplantation Recipient, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in
Active, not recruiting
- Hematopoietic Cell Transplantation Recipient
- +3 more
- Allogeneic Bone Marrow Transplantation
- +10 more
-
Houston, TexasM D Anderson Cancer Center
Aug 18, 2022
Advanced Lymphoma, Advanced Malignant Solid Tumor, Advanced Pancreatic Carcinoma Trial in New Haven (BET Bromodomain Inhibitor
Recruiting
- Advanced Lymphoma
- +13 more
- BET Bromodomain Inhibitor ZEN-3694
- +2 more
-
New Haven, ConnecticutYale University Cancer Center LAO
Jun 29, 2022
Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia Trial in
Recruiting
- Myelodysplastic Syndrome
- +16 more
- Computed Tomography
- +6 more
-
Scottsdale, Arizona
- +2 more
Feb 3, 2022
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma Trial in Seattle (procedure,
Completed
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +7 more
- Autologous Hematopoietic Stem Cell Transplantation
- +7 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 29, 2020
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma Trial in Seattle
Terminated
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +5 more
- Autologous Hematopoietic Stem Cell Transplantation
- +2 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Mar 26, 2020